期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

免疫抑制剂的治疗药物监测概况及研究进展 被引量：3

下载PDF
导出
摘要 随着临床治疗中器官移植技术的发展和广泛应用，免疫抑制剂的应用受到越来越多的关注。免疫抑制剂通过抑制淋巴细胞的功能，减少移植物排斥反应的发生，延长移植物存活时间。但由于免疫抑制剂具有较强的毒性，尤其是肾毒性，因此，常常需要在低剂量发生移植物排斥和高剂量产生毒性之间取得平衡。
作者 付鹏
机构地区 天津市第一中心医院药学部
出处 《实用器官移植电子杂志》 2015年第5期307-312,共6页 Practical Journal of Organ Transplantation(Electronic Version)
关键词 免疫抑制剂 治疗药物监测 移植物排斥反应 霉酚酸 器官移植技术 环孢素 硫唑嘌呤 血药浓度 药物受体 药代动力学
分类号 R617 [医药卫生—外科学]
  • 相关文献

参考文献33

  • 1Johannessen SI, Battino D, Berry DJ, et al. Therapeutic drug monitoring of the newer antiepileptic drugs [ J]. Ther Drug Monit, 2003,25 (3) :347-363.
  • 2Hiemke C, Dragicevic A, Grfinder G, et al. The rapeutic monitoring of new antipsychotic drugs [J ]. Ther Drug Monit, 2004,26 (2) : 156-160.
  • 3Bengtsson F. Therapeutic drug monitoring of psychotropic drugs. TDM " nouveau" [ J ]. Ther Drug Monit,2004,26 (2) : 145-151.
  • 4Eap CB, Jaquenoud Sirot E, Baumann P. Therapeutic monitoring of antidepressants in the era of pharmacogenetics studies [ J ]. Ther Drug Monit,2004,26 (2) : 152-155.
  • 5Schou M. Forty years of lithium treatment [ J ]. Arch Gen Psychiatry, 1997,54 ( 1 ) : 9-13.
  • 6Fraaij PL, Rakhmanina N, Burger DM, et al. Therapeutic drug monitoring in children with HIV/ AIDS [ J ]. Ther Drug Monit, 2004,26 (2) : 122-126.
  • 7Akinobu Hamada. Deveiopment of an Individualized Therapy for Establishing the Optimal Dosage by the Pharmacokinetics Profiles of Anticancer Agents [ J ]. Yakugaku Zasshi,2005,125 (8) : 631-637.
  • 8Donnelly JG. Pharmacogenetics in cancer chemotherapy : balancing toxicity and response [J]. Ther Drug Monit,2004,26(2): 231-235.
  • 9Erlichman C, Soldin S J, Thiessen J J, et al. Disposition of total and free cisplatin on two consecutive treatment cycles in patients with ovarian cancer [ J ]. Cancer Chemother Pharmacol, 1987,19 ( 1 ) : 75-79.
  • 10Holt DW, Johnston A. Monitoring immunosuppressive drugs : has it a future? [ J ]. Ther Drug Monit, 2004,26 (3) : 244-247.

二级参考文献17

  • 1Scott LJ,McKeage K,Keam SJ. Tacrolimus:a further update of its use in the management of organ transplantation[J].Drugs,2003,(12):1247-1297.
  • 2Singh R,Srivastava A,Kapoor R. Impact of CYP3A5 and CYP3A4 gene polymorphisms on dose requirement of calcineurin inhibitors,cyclosporine and tacrolimus,in renal allograft recipients of North India[J].Naunyn-Schmiedeberg's Archives of Pharmacology,2009,(02):169-177.doi:10.1007/s00210-009-0415-y.
  • 3Zhang J,Zhang X,Liu L. Value of CYP3A5 genotyping on determining initial dosages of tacrolimus for Chinese renal transplant recipients[J].Transplantation Proceedings,2010,(09):3459-3464.
  • 4Staatz CE,Goodman LK,Tett SE. Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors:Part I[J].Clinical Pharmacokinetics,2010,(03):141-175.
  • 5Qiu F,He XJ,Sun YX. Influence of ABCB1,CYP3A4*18B and CYP3A5*3 polymorphisms on cyclosporine A pharmacokinetics in bone marrow transplant recipients[J].PHARMACOLOGICAL REPORTS,2011,(03):815-825.
  • 6MacPhee IA. Pharmacogenetic biomarkers:cytochrome P4503A5[J].Clinica Chimica Acta,2012,(17-18):1312-1317.
  • 7Staatz CE,Goodman LK,Tett SE. Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors:Part II[J].Clinical Pharmacokinetics,2010,(04):207-221.
  • 8Li L,Li CJ,Zheng L. Tacrolimus dosing in Chinese renal transplant recipients:a population-based pharmacogenetics study[J].European Journal of Clinical Pharmacology,2011,(08):787-795.
  • 9de Jonge H,Kuypers DR. Pharmacogenetics in solid organ transplantation:current status and future directions[J].Transplantation Reviews(Orlando),2008,(01):6-20.
  • 10Gervasini G,Garcia M,Macias RM. Impact of genetic polymorphisms on tacrolimus pharmacokinetics and the clinical outcome of renal transplantation[J].Transplant International,2012,(04):471-480.

共引文献16

同被引文献11

引证文献3

二级引证文献6

实用器官移植电子杂志
2015年 第5期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部